Delix Therapeutics Inc., a Boston-based company that’s researching compounds similar to psychedelic drugs like LSD but without their hallucinogenic effects, raised $70 million in an initial funding round, according to Chief Executive Officer Mark Rus.
The company, which has yet to do clinical trials, focuses on mental-health treatments and has a stated mission of “rewiring the brain to heal the mind.” It has patents for over 1,000 novel compounds that help the brain’s ability to adapt, and is homing in on two in particular, Rus said in a phone interview. He said these have shown in preclinical work to match or exceed the properties of ketamine, a mind-altering drug that is effective in treating depression, pain and other conditions.
"Startup" - Google News
September 27, 2021 at 05:30PM
https://ift.tt/3ibjvEE
Startup Raises Money for Psychedelics Without a Trip - Bloomberg
"Startup" - Google News
https://ift.tt/2MXTQ2S
https://ift.tt/2z7gkKJ
No comments:
Post a Comment